Which treatment fits your hip cartilage damage?

For many patients with hip cartilage damage, the first question is a practical one: does this need an operation, or is there a clinic-based option? The answer depends largely on the nature of the damage itself.

AMIC (Autologous Matrix-Induced Chondrogenesis) is a surgical procedure carried out in an operating theatre under general or spinal anaesthesia, designed to reconstruct a focal, contained area of cartilage loss from the bone bed upward. The ChondroFiller injection, by contrast, is delivered as an outpatient appointment under local anaesthesia — an ultrasound-guided injectable collagen scaffold that lays a protective matrix over worn hip joint surfaces without any surgical incision.

The choice between them turns primarily on the type of cartilage damage present: whether it is a discrete, focal lesion with healthy margins, or a more diffuse pattern of wear. Patient age and fitness for anaesthesia also play a role.

Neither pathway suits every hip. Both are hip-preservation strategies — their shared goal is to reduce pain and delay or avoid the need for hip replacement.

Why hip cartilage struggles to repair itself

Articular cartilage has no blood supply. Unlike bone or muscle, it cannot mount a healing response when it is injured — there are no vessels to deliver the repair cells that most tissues rely on. Damage tends to stay damaged.

The hip joint compounds this problem. As a load-bearing ball-and-socket joint, it transmits body weight with every step and guides a wide arc of movement from walking to rotation. Once the cartilage surface is breached, that combination of compressive force and shear stress accelerates the deterioration of the surrounding tissue.

Grade III and IV chondral defects represent the clinical threshold where this matters most. Grade III describes near-full-thickness loss with the cartilage surface severely eroded; Grade IV means the underlying bone is exposed. At these stages, the joint's own resources are insufficient to restore meaningful cover, and without intervention a focal lesion may spread into the diffuse joint-wide arthritis that typically makes hip replacement the only remaining option.

It is at this Grade III/IV threshold that both AMIC and the ChondroFiller injection become relevant — one rebuilding from exposed bone upward, the other providing a protective scaffold over what surface remains.

AMIC: how the surgical approach works in the hip

AMIC works in two connected steps. The surgeon first performs microfracture — drilling or picking through the subchondral bone at the base of the defect to release marrow-derived progenitor cells and growth factors into the prepared site. Without further intervention, those cells tend to produce fibrocartilage: structurally weaker tissue that typically deteriorates within a few years. The second step is what makes AMIC distinct: a bi-layer collagen I/III membrane is secured over the lesion, trapping the marrow clot and channelling the progenitor cells into a structured scaffold that supports more organised, cartilage-like repair tissue.

The procedure is carried out in theatre under arthroscopic visualisation, and the joint must be dried so that the membrane can adhere correctly to the bone bed.

Patient selection is specific. AMIC is best suited to isolated, contained focal defects of approximately 3–4 cm² in younger, active patients with healthy cartilage at the surrounding margins. Diffuse or advanced joint-wide arthritis lies outside its scope.

The short-to-medium-term outcomes data are encouraging. Registry data from 57 patients (mean age 37.3 years, mean defect 3.4 cm²) showed significant reduction in VAS pain scores at both one- and two-year follow-up (p<0.001). A randomised controlled trial by Fossum et al. in 41 patients found results comparable to autologous chondrocyte implantation (ACI), a more resource-intensive two-stage procedure — supporting AMIC as a practical single-stage alternative.

Durability remains the principal open question. Kreuz et al. documented a meaningful decline in functional scores between 18 and 36 months in marrow-stimulation series, and Solheim et al. found fewer than 60% of cases surviving at three years when microfracture was used without augmentation. AMIC's collagen membrane is designed to improve on that trajectory, and the short-term data suggest it may — but evidence beyond three years has not yet confirmed whether the benefit holds.

ChondroFiller injection: the outpatient route for hip cartilage

Rather than rebuilding from the bone bed, the ChondroFiller injection takes an entirely different starting point. It is an acellular Type I collagen scaffold — CE-marked as a Class III medical device — administered as a 30–45 minute outpatient appointment under local anaesthesia, with no operating theatre, no general anaesthesia, and same-day discharge.

Under ultrasound guidance, the liquid collagen is injected directly into the hip joint, where it gels in situ and coats the worn articular surface. Crucially, the product contains no cells of its own. It works through matrix-induced chondrogenesis: once placed, the collagen matrix acts as a chemotactic scaffold, drawing the patient's own chondrocytes and mesenchymal stem cells in from surrounding tissue and providing a structural environment that supports cartilage-like repair from within the joint space.

Patient eligibility is considerably broader than for AMIC. There is no strict upper age limit and no defect-size ceiling for the injection pathway; it can be used for focal Grade III/IV lesions, more diffuse OA-related hip cartilage loss, and damage associated with femoroacetabular impingement (FAI).

Published hip outcomes from multi-centre studies — not yet from a single randomised controlled trial in the hip specifically — report a Harris Hip Score improvement of +33 points and MOCART MRI regeneration scores between 70 and 87. Over 19,000 ChondroFiller cases have now been performed globally, providing a meaningful base of post-market clinical experience, though the long-term hip-specific evidence base is still developing and individual outcomes vary by defect size, cartilage quality, and patient factors.

Surgery or injection: how AMIC and ChondroFiller compare

The most useful frame here is patient profile and clinical context — not a ranking of one approach over the other.

Setting is the starkest contrast, though the reader will already have a clear picture of it: theatre, anaesthesia, and a post-surgical recovery period on one side; a 30–45 minute clinic appointment with same-day return home on the other. For patients in Lincolnshire weighing access and time off work, that practical difference can be as influential as any clinical factor.

On defect profile, AMIC's scope is narrower — it requires clearly bordered damage with healthy surrounding margins, the kind of contained focal lesion where the membrane can be anchored and supported. The ChondroFiller injection pathway encompasses that picture but extends further: diffuse Grade III/IV hip wear and FAI-related damage that falls outside AMIC's surgical preparation are both within its eligibility range, including in older patients.

The evidence base for each reflects those different scopes. AMIC carries RCT support — the Fossum et al. 41-patient trial — alongside registry data, but durability beyond three years remains an open question. Published hip outcomes for ChondroFiller injection, including the +33 Harris Hip Score improvement and MOCART regeneration scores of 70–87 from multi-centre studies, come from clinical series rather than a single randomised controlled trial. Critically, no direct head-to-head trial comparing the two techniques specifically in the hip joint currently exists; both evidence bases should be considered on their own terms.

Where the pathways can converge is in large, unstable focal lesions managed surgically: in that setting, ChondroFiller may be applied arthroscopically as a scaffold facilitator alongside AMIC — an external surgical context, not the current outpatient injection service. For most patients, the two techniques address distinct clinical profiles rather than the same one.

Getting a hip cartilage assessment at Lincolnshire Hip

Choosing between these two pathways cannot be done from symptoms alone. MRI assessment of defect size, grade, and distribution — combined with clinical history and a patient's fitness for, or preference about, surgery — is what shapes the conversation at first consultation. As a practical orientation: a contained focal lesion under roughly 4 cm² with healthy surrounding margins tends to direct discussion toward AMIC; more diffuse hip wear, advanced OA, or a preference for an outpatient route shifts the focus toward ChondroFiller injection. Many assessments are not straightforwardly one or the other, which is precisely why the imaging review comes first.

Both pathways are available through Lincolnshire Hip, with Professor Paul Lee consulting at Grantham and Sleaford. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

1. [1] Autologous matrix-induced chondrogenesis. https://en.wikipedia.org/?curid=29760859 https://en.wikipedia.org/?curid=29760859